CA3094139A1 - Compositions - Google Patents

Compositions Download PDF

Info

Publication number
CA3094139A1
CA3094139A1 CA3094139A CA3094139A CA3094139A1 CA 3094139 A1 CA3094139 A1 CA 3094139A1 CA 3094139 A CA3094139 A CA 3094139A CA 3094139 A CA3094139 A CA 3094139A CA 3094139 A1 CA3094139 A1 CA 3094139A1
Authority
CA
Canada
Prior art keywords
flagellin
polypeptide
flagellin polypeptide
compositions
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3094139A
Other languages
English (en)
French (fr)
Inventor
Imke Elisabeth MULDER
Emma RAFTIS
Emma Elizabeth Clare HENNESSY
Delphine Louise Claudette LAUTE-CALY
Philip COWIE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
4D Pharma Research Ltd
Original Assignee
4D Pharma Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1804384.4A external-priority patent/GB201804384D0/en
Priority claimed from GBGB1809953.1A external-priority patent/GB201809953D0/en
Priority claimed from GBGB1811900.8A external-priority patent/GB201811900D0/en
Priority claimed from GBGB1812378.6A external-priority patent/GB201812378D0/en
Priority claimed from GBGB1813444.5A external-priority patent/GB201813444D0/en
Priority claimed from GBGB1813423.9A external-priority patent/GB201813423D0/en
Priority claimed from GBGB1816834.4A external-priority patent/GB201816834D0/en
Priority claimed from GBGB1817641.2A external-priority patent/GB201817641D0/en
Priority claimed from GBGB1901218.6A external-priority patent/GB201901218D0/en
Priority claimed from GBGB1901199.8A external-priority patent/GB201901199D0/en
Priority claimed from GBGB1901992.6A external-priority patent/GB201901992D0/en
Priority claimed from GBGB1901993.4A external-priority patent/GB201901993D0/en
Application filed by 4D Pharma Research Ltd filed Critical 4D Pharma Research Ltd
Publication of CA3094139A1 publication Critical patent/CA3094139A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Rheumatology (AREA)
CA3094139A 2018-03-19 2019-03-19 Compositions Abandoned CA3094139A1 (en)

Applications Claiming Priority (27)

Application Number Priority Date Filing Date Title
GB1804384.4 2018-03-19
GBGB1804384.4A GB201804384D0 (en) 2018-03-19 2018-03-19 Compositions
EP18178350 2018-06-18
GBGB1809953.1A GB201809953D0 (en) 2018-06-18 2018-06-18 Compositions
EP18178350.7 2018-06-18
GB1809953.1 2018-06-18
GBGB1811900.8A GB201811900D0 (en) 2018-07-20 2018-07-20 Compositions comprising bacterial strains
GB1811900.8 2018-07-20
GB1812378.6 2018-07-30
GBGB1812378.6A GB201812378D0 (en) 2018-07-30 2018-07-30 Compositions comprising bacterial strains
GB1813444.5 2018-08-17
GB1813423.9 2018-08-17
GBGB1813444.5A GB201813444D0 (en) 2018-08-17 2018-08-17 Compositions
GBGB1813423.9A GB201813423D0 (en) 2018-08-17 2018-08-17 Compositions comprising bacterial strains
GBGB1816834.4A GB201816834D0 (en) 2018-10-16 2018-10-16 Compositions
GB1816834.4 2018-10-16
GB1817641.2 2018-10-29
GBGB1817641.2A GB201817641D0 (en) 2018-10-29 2018-10-29 Compositions comprising bacterial strains
GB1901199.8 2019-01-29
GB1901218.6 2019-01-29
GBGB1901218.6A GB201901218D0 (en) 2019-01-29 2019-01-29 Compositions
GBGB1901199.8A GB201901199D0 (en) 2019-01-29 2019-01-29 Compositions comprising bacterial strains
GB1901992.6 2019-02-13
GB1901993.4 2019-02-13
GBGB1901992.6A GB201901992D0 (en) 2019-02-13 2019-02-13 Compositions comprising bacterial strains
GBGB1901993.4A GB201901993D0 (en) 2019-02-13 2019-02-13 Compositions
PCT/EP2019/056809 WO2019180000A1 (en) 2018-03-19 2019-03-19 Compositions

Publications (1)

Publication Number Publication Date
CA3094139A1 true CA3094139A1 (en) 2019-09-26

Family

ID=65955185

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3094139A Abandoned CA3094139A1 (en) 2018-03-19 2019-03-19 Compositions
CA3094297A Pending CA3094297A1 (en) 2018-03-19 2019-03-19 Compositions comprising bacterial strains

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3094297A Pending CA3094297A1 (en) 2018-03-19 2019-03-19 Compositions comprising bacterial strains

Country Status (25)

Country Link
US (3) US11419931B2 (OSRAM)
EP (3) EP3768285A1 (OSRAM)
JP (3) JP2021518414A (OSRAM)
KR (2) KR102578117B1 (OSRAM)
CN (2) CN111886018A (OSRAM)
AU (2) AU2019238358A1 (OSRAM)
BR (2) BR112020019008A2 (OSRAM)
CA (2) CA3094139A1 (OSRAM)
CY (1) CY1125104T1 (OSRAM)
DK (1) DK3768284T3 (OSRAM)
ES (1) ES2908826T3 (OSRAM)
HR (1) HRP20220368T1 (OSRAM)
HU (1) HUE058151T2 (OSRAM)
IL (2) IL277421B (OSRAM)
LT (1) LT3768284T (OSRAM)
MA (1) MA52128A (OSRAM)
MD (1) MD3768284T2 (OSRAM)
MX (2) MX2020009736A (OSRAM)
PL (1) PL3768284T3 (OSRAM)
RS (1) RS63090B1 (OSRAM)
SG (2) SG11202009259VA (OSRAM)
SI (1) SI3768284T1 (OSRAM)
SM (1) SMT202200111T1 (OSRAM)
TW (2) TW202003000A (OSRAM)
WO (2) WO2019180000A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3768285A1 (en) 2018-03-19 2021-01-27 4D Pharma Research Limited Compositions comprising bacterial strains
WO2021113500A2 (en) * 2019-12-03 2021-06-10 Board Of Regents, The University Of Texas System Combination therapies for the treatment of cancer
US20230256033A1 (en) * 2020-06-09 2023-08-17 Flagship Pioneering Innovations Vi, Llc Physiologically acceptable compositions containing microorganisms or microbial products
US12350300B2 (en) 2021-10-08 2025-07-08 Iowa State University Research Foundation, Inc. Use of dopamine producing products to increase vaccine efficacy
CN113999923B (zh) * 2021-11-25 2024-05-14 上海金翌生物科技有限公司 小柳-原田综合症标志微生物及其应用
CN115287243B (zh) * 2022-04-15 2023-06-06 集美大学 一株变形假单胞菌flgK基因沉默菌株及其构建方法
JPWO2024096122A1 (OSRAM) * 2022-11-04 2024-05-10
KR102878250B1 (ko) 2023-01-11 2025-10-31 서울대학교산학협력단 코리스메이트 뮤테이즈 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 포함하는 암 예방 또는 치료용 조성물

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
JPH08259450A (ja) 1995-03-17 1996-10-08 Nichinichi Seiyaku Kk インターフェロン産生増強剤
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
EP0904784A1 (en) 1997-09-22 1999-03-31 N.V. Nutricia Probiotic nutritional preparation
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
US20040009937A1 (en) * 2002-01-31 2004-01-15 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
US20080025977A1 (en) 2003-04-14 2008-01-31 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US20060228369A1 (en) 2005-04-11 2006-10-12 Program For Appropriate Technology In Health Stabilization and preservation of temperature-sensitive vaccines
JP2007116991A (ja) 2005-10-28 2007-05-17 Eternal Light General Institute Inc 機能性食品
RU2420538C2 (ru) 2006-10-27 2011-06-10 Пфайзер Продактс Инк. Жесткие капсулы из гидроксипропилметилцеллюлозы и способ их получения
EP1958647A1 (en) 2007-02-15 2008-08-20 Helmholtz-Zentrum für Infektionsforschung GmbH Pharmaceutical composition with bacteria for tumor treatment
JP5187642B2 (ja) 2007-03-19 2013-04-24 森下仁丹株式会社 経口ワクチン
JP2011519834A (ja) * 2008-04-25 2011-07-14 インスティチュート フォー システムズ バイオロジー フラジェリンポリペプチドワクチン
CA2777198C (en) * 2009-10-06 2018-07-24 Panacela Labs, Inc. Use of toll-like receptor and agonist for treating cancer
KR20140030132A (ko) 2011-01-10 2014-03-11 클리브랜드 바이오랩스, 아이엔씨. 암을 치료하기 위한 톨-유사 수용체 효능제의 용도
EP2731572B1 (en) 2011-07-13 2021-04-07 Pharmaxis Ltd. Improvements relating to delivery devices
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
ES2408279B1 (es) 2011-12-15 2014-09-09 Universidad De Las Palmas De Gran Canaria Bacteria acido láctica probiótica
FR2989002B1 (fr) 2012-04-10 2015-05-15 Beepratte Lab Compositions a base de probiotiques et d'un complexe beepollen/argile, leur preparation et leurs utilisations en nutrition et therapeutique
CA2884816A1 (en) 2012-09-13 2014-03-20 Massachusetts Institute Of Technology Programmable drug delivery profiles of tumor-targeted bacteria
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
CA2935635C (en) * 2014-02-12 2023-05-09 Transalgae Israel Ltd. Algal based edible vaccines
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
AU2016357554B2 (en) * 2015-11-20 2019-04-04 Cj Bioscience, Inc. Compositions comprising bacterial strains
GB201520502D0 (en) * 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
TW201907931A (zh) * 2017-05-24 2019-03-01 英商4D製藥研究有限公司 包含細菌菌株之組合物
TW201906620A (zh) 2017-07-05 2019-02-16 美商艾弗洛生物科技股份有限公司 使用動物雙岐桿菌乳亞種 (bifidobacterium animalis ssp. lactis) 治療癌症之組合物及方法
MA49982A (fr) 2017-08-10 2020-06-17 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
EP3768285A1 (en) 2018-03-19 2021-01-27 4D Pharma Research Limited Compositions comprising bacterial strains

Also Published As

Publication number Publication date
EP3768285A1 (en) 2021-01-27
CA3094297A1 (en) 2019-09-26
BR112020018818A2 (pt) 2021-05-04
CN111886018A (zh) 2020-11-03
US11419931B2 (en) 2022-08-23
AU2019239048A1 (en) 2020-11-05
MX2020009736A (es) 2021-01-08
SG11202009254YA (en) 2020-10-29
KR20210003096A (ko) 2021-01-11
CN112004543A (zh) 2020-11-27
MX2020009733A (es) 2022-10-27
DK3768284T3 (da) 2022-03-07
IL277422A (en) 2020-11-30
SMT202200111T1 (it) 2022-05-12
KR20200134255A (ko) 2020-12-01
HRP20220368T1 (hr) 2022-06-24
WO2019180000A1 (en) 2019-09-26
US20210138058A1 (en) 2021-05-13
AU2019238358A1 (en) 2020-10-08
SI3768284T1 (sl) 2022-04-29
HUE058151T2 (hu) 2022-07-28
US20220257745A1 (en) 2022-08-18
KR102578117B1 (ko) 2023-09-12
TW202003001A (zh) 2020-01-16
BR112020019008A2 (pt) 2020-12-29
SG11202009259VA (en) 2020-10-29
EP4046644A1 (en) 2022-08-24
LT3768284T (lt) 2022-04-11
MD3768284T2 (ro) 2022-06-30
MA52128A (fr) 2021-01-27
IL277421B (en) 2022-04-01
PL3768284T3 (pl) 2022-04-11
AU2019239048B2 (en) 2022-07-21
EP3768284B1 (en) 2022-01-05
IL277421A (en) 2020-11-30
JP2023100747A (ja) 2023-07-19
ES2908826T3 (es) 2022-05-04
US20210169950A1 (en) 2021-06-10
WO2019180051A1 (en) 2019-09-26
US11857614B2 (en) 2024-01-02
JP2021518414A (ja) 2021-08-02
CY1125104T1 (el) 2024-02-16
EP3768284A1 (en) 2021-01-27
JP2021518129A (ja) 2021-08-02
RS63090B1 (sr) 2022-04-29
TW202003000A (zh) 2020-01-16

Similar Documents

Publication Publication Date Title
US11857614B2 (en) Enterococcus gallinarum flagellin polypeptides
KR20180096591A (ko) 광범위 인플루엔자 바이러스 백신
AU2023200562A1 (en) Compositions comprising bacterial strains
AU2019204809A1 (en) Compositions comprising bacterial strains
JP6786074B2 (ja) エキソソーム標的ｄｎａワクチン
KR102823291B1 (ko) 종양-관련된 항원 에피토프의 미생물 서열 변이체
US12472245B2 (en) Compositions and methods
JP7247097B2 (ja) がん免疫療法のための新規ｐｄ－ｌ１標的ｄｎａワクチン
JP2021521798A (ja) がんに対する組換え型の治療介入
KR20260020489A (ko) Rna를 안정화시키는 방법
CN110022894A (zh) 用于癌症疗法的免疫原性化合物
HK40043598B (en) Compositions of entrecoccus flagellin for use in therapy
HK40043598A (en) Compositions of entrecoccus flagellin for use in therapy
OA20217A (en) Compositions.
JP2024054375A (ja) エキソソーム標的ｄｎａワクチン
EP3541412A1 (en) Cyaa polypeptides as immune enhancer
WO2018091142A1 (en) Cyaa polypeptides as immune enhancer
Mahbuba Generation and evaluation of SMT-expressing Lactococcus lactis live vaccines against visceral leishmaniasis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220210

FZDE Discontinued

Effective date: 20230725